Only around five months ago, AstraZeneca’s (LSE: AZN) share price hit a point that made the firm the UK’s first £200bn listing.
Now, it is down 20% from its 3 September 12-month traded high of £133.38.
I think three key reasons will propel it much higher again over time.
Enormous earnings growth potential
Ultimately, it is earnings growth that powers a firm’s share price (and dividend) higher. Analysts forecast that AstraZeneca’s earnings will grow by 16.9% each year to the end of 2027.
Its nine-month results saw its 2024 earnings per share (EPS) growth forecast increase to a high-teens percentage from the mid-teens. This came after an 11% jump in EPS over the period to $6.12 (£4.97).
And both followed a 19% increase in total revenue, to $39.182bn. Revenue is the total income a company generates, while earnings are what remains after expenses are subtracted. In the long term, AstraZeneca forecasts $80bn+ in revenues by 2030, against $45.8bn at the end of 2023.
Positioned for a major demographic shift
According to the World Health Organization, 1.4bn people will be aged 60+ by 2030 compared to 1bn now. By 2050, that number will be 2.1bn. At that point, the number of people aged 80+ will triple to 426m.
As older age brings declining health, the demand for medical assistance, including drugs, increases.
AstraZeneca currently has 189 new drugs at various stages of development in its pipeline. By comparison, its leading UK peer GSK has 71.
Moreover, the firm announced at its 15 November ‘Health Equity Event’ that it is working on multiple game-changing new medicines. These focus on cutting-edge areas such as smart chemotherapy, gene therapy and editing, and next-generation immunotherapy.
Extreme current undervaluation
On the key price-to-book ratio of stock valuation, AstraZeneca trades at only 5.1. This is bottom of its competitor group, which averages 32.9. So, it looks very undervalued on this basis.
The same is true on the price-to-sales and price-to-earnings ratios. On the former, it trades at just 4 compared to its competitors’ average of 11. And on the latter, it is at 31.7 against a 53.9 average for its peers.
A discounted cash flow analysis shows the shares are currently 60% undervalued. Therefore, technically a fair price is £266.18 rather than the present £106.47.
They may go lower or higher than that, given market vagaries. But it underlines to me that they look a steal at the current price.
Will I buy more?
Against all this are two main risks in my view. The first is the possibility of penalties being imposed when Chinese authorities conclude their investigations of its China operations.
The second is legal action for damages from AstraZeneca’s alleged failure to inform investors early enough of these investigations.
That said, AstraZeneca raised its key performance guidance after China launched its investigations. Additionally, I see legal action against pharmaceutical firms as already largely costed into that business and the share price.
Consequently, I will be buying more AstraZeneca shares very soon.
The post 3 key reasons why AstraZeneca’s share price looks a steal to me right now appeared first on The Motley Fool UK.
But there may be an even bigger investment opportunity that’s caught my eye:
Investing in AI: 3 Stocks with Huge Potential!
🤖 Are you fascinated by the potential of AI? 🤖
Imagine investing in cutting-edge technology just once, then watching as it evolves and grows, transforming industries and potentially even yielding substantial returns.
If the idea of being part of the AI revolution excites you, along with the prospect of significant potential gains on your initial investment…
Then you won’t want to miss this special report inside Motley Fool Share Advisor – ‘AI Front Runners: 3 Surprising Stocks Riding The AI Wave’!
And today, we’re giving you exclusive access to ONE of these top AI stock picks, absolutely free!
Get your free AI stock pick
More reading
These are my top 3 defensive shares to buy in 2025!
FTSE shares in 2025: an opportunity to get rich?
I asked ChatGPT for the best UK stocks for me to buy for 2025. Here are 5 names it gave me
If the market shut down for 10 years, I’d be happy to hold these 2 FTSE 100 shares
Analysts are saying the AstraZeneca share price looks cheap despite China turmoil
Simon Watkins has positions in AstraZeneca Plc. The Motley Fool UK has recommended AstraZeneca Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
